Floatz logo

q702

Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

Mayo ClinicSmall moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm cohort.

Asset / SponsorPhaseRating
Tagraxofusp
French Innovative Leukemia Organisation
Phase 2BB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2BB
Fludarabine
Fred Hutchinson Cancer Center
Phase 2BB
METHOTREXATE
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2BB
Fludarabine
Therapeutic Advances in Childhood Leukemia Consortium
Phase 2B

View all 48 →

Same molecule, other indications

q702 is also rated in:

hepatocellular carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
Erdheim-Chester diseaseDormant
CC
Indicative ·
43 / 100
View asset →
sinus histiocytosis with massive lymphadenopathyDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →